RCOR

Rockwell Medical Appoints Joan Lau, Ph.D. to the Company's Board of Directors

Retrieved on: 
Tuesday, October 17, 2023
Medical Supplies, Medical Devices, Health, Research, Science, Biotechnology, BSE, Philadelphia Orchestra, Multimedia, University, NYSE, MBA, Acquisition, RCOR, Rockwell, Business, Partner, Philadelphia, Dialysis, Merck & Co., Rockwell Medical, BDN, Immunome, Doctor of Philosophy, Growth, Trustee, Brandywine Realty Trust, Penn State Board of Trustees, University of Cincinnati, The Company, Patient, Wharton School of the University of Pennsylvania, Management, Biological engineering, Neuroscience

Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that the Company appointed Joan Lau, Ph.D. to its board of directors.

Key Points: 
  • Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that the Company appointed Joan Lau, Ph.D. to its board of directors.
  • Dr. Lau's appointment increases Rockwell Medical's board of directors to seven members.
  • View the full release here: https://www.businesswire.com/news/home/20231017906241/en/
    "We are pleased to welcome Joan to Rockwell Medical's board of directors," said Robert S. Radie , Chairman of the Board of Directors at Rockwell Medical.
  • "Joan has founded, led, and scaled a number of biotechnology companies throughout her career, possessing a significant amount of business development, operational, and M&A expertise.

Rocket Pharmaceuticals Completes Acquisition of Renovacor

Retrieved on: 
Thursday, December 1, 2022
Health, Genetics, Research, Science, Pharmaceutical, Cardiology, Biotechnology, LVV, RCOR, Communication, Attention, Pyruvate kinase deficiency, PKD, Genetic disorder, Uncertainty, Patient, Heart failure, Medication, Fanconi anemia, Annual report, Bone marrow failure, DCM, Disease, NYSE, FA, Heart, Risk, Danon disease, AAV, Acquisition, Pharmaceutical industry

Under the terms of the merger agreement entered into on September 19, 2022, Renovacor shareholders received, for each share of Renovacor common stock, 0.1763 shares of Rocket common stock.

Key Points: 
  • Under the terms of the merger agreement entered into on September 19, 2022, Renovacor shareholders received, for each share of Renovacor common stock, 0.1763 shares of Rocket common stock.
  • The acquisition provides Rocket with Renovacors most advanced program, REN-001, an AAV-based gene therapy targeting BAG3-associated dilated cardiomyopathy (DCM), a severe form of heart failure.
  • Additionally, Rocket gains access to world-class scientific collaborators, a robust intellectual property portfolio and personnel with expertise in BAG3-DCM.
  • Neither Renovacor nor Rocket gives any assurance that it will achieve its expectations.

SHAREHOLDER ALERT: Contact the M&A Class Action Firm to Inquire about its Investigation of the Merger – SBCF, OYST, RCOR, SMBC

Retrieved on: 
Monday, November 28, 2022
RCOR, United States Court of Appeals for the Ninth Circuit, Telephone, Monteverde, Mergers and acquisitions, Lawyer, Empire, Greenhouse effect (United States Supreme Court), Security (finance), NYSE, SBCF, Martindale-Hubbell, CVR Partners, Viatris, Rising Star, Investment, Supreme court, Acquisition, SMBC, Citizenship

Under the terms of the merger, Professional Holding Corp. shareholders are expected to receive 0.8909 shares of SBCF per share they own.

Key Points: 
  • Under the terms of the merger, Professional Holding Corp. shareholders are expected to receive 0.8909 shares of SBCF per share they own.
  • We are a national class action securities litigation law firm that has recovered millions of dollars and is committed to protecting shareholders from corporate wrongdoing.
  • We were listed in the Top 50 in the 2018-2021 ISS Securities Class Action Services Report.
  • Also, we have recovered or secured over a dozen cash common funds for shareholders in mergers & acquisitions class action cases.

INVESTOR ALERT: The M&A Class Action Firm Continues Investigating the Merger –TALO, RCOR, BTRS, AKUS

Retrieved on: 
Tuesday, November 15, 2022
AKUS, RCOR, United States Court of Appeals for the Ninth Circuit, BTRS, Telephone, Monteverde, Mergers and acquisitions, Lawyer, Eli Lilly and Company, Empire, Greenhouse effect (United States Supreme Court), TALO, Security (finance), NYSE, Akouo, Martindale-Hubbell, Supreme court, Rising Star, Investment, EQT, Acquisition

Under the terms of the agreement, RCOR shareholders will receive 0.1676 shares of Rocket per share they own.

Key Points: 
  • Under the terms of the agreement, RCOR shareholders will receive 0.1676 shares of Rocket per share they own.
  • We are a national class action securities litigation law firm that has recovered millions of dollars and is committed to protecting shareholders from corporate wrongdoing.
  • We were listed in the Top 50 in the 2018-2021 ISS Securities Class Action Services Report.
  • Also, we have recovered or secured over a dozen cash common funds for shareholders in mergers & acquisitions class action cases.

EQUITY ALERT: The M&A Class Action Firm Continues Investigating the Merger – RCOR, TALO, PEBO, SMBC

Retrieved on: 
Tuesday, November 1, 2022
Security (finance), TALO, Securities Exchange Act of 1934, Mergers and acquisitions, Private Securities Litigation Reform Act, Acquisition, Rising Star, GLOBE, NYSE, Nasdaq, Monteverde, Empire, United States Court of Appeals for the Ninth Circuit, RCOR, Supreme court, Telephone, Lawyer, Investment, SMBC, Martindale-Hubbell, Greenhouse effect (United States Supreme Court), Citizenship

Talos Energy Inc. (NYSE: TALO ), relating to its proposed merger with EnVen Energy Corp. Click here for more information: https://www.monteverdelaw.com/case/talos-energy-inc .

Key Points: 
  • Talos Energy Inc. (NYSE: TALO ), relating to its proposed merger with EnVen Energy Corp. Click here for more information: https://www.monteverdelaw.com/case/talos-energy-inc .
  • We are a national class action securities litigation law firm that has recovered millions of dollars and is committed to protecting shareholders from corporate wrongdoing.
  • We were listed in the Top 50 in the 2018-2021 ISS Securities Class Action Services Report.
  • Also, we have recovered or secured over a dozen cash common funds for shareholders in mergers & acquisitions class action cases.

EQUITY ALERT: The M&A Class Action Firm Continues Investigating the Merger - CFCX, BTRS, RCOR, TALO

Retrieved on: 
Friday, October 28, 2022
Security (finance), Acquisition, Nasdaq, Monteverde, Securities Exchange Act of 1934, BTRS, Lawyer, EQT, United States Court of Appeals for the Ninth Circuit, Private Securities Litigation Reform Act, OTC, Supreme, Greenhouse effect (United States Supreme Court), Polish–Lithuanian Commonwealth, Mergers and acquisitions, Telephone, Investment, NYSE, RCOR, Martindale-Hubbell, CFCX, TALO

Under the terms of the agreement, CFCX shareholders are expected to receive 1.09 shares of First Commonwealth per share they own.

Key Points: 
  • Under the terms of the agreement, CFCX shareholders are expected to receive 1.09 shares of First Commonwealth per share they own.
  • Talos Energy Inc. (NYSE: TALO ), relating to its proposed merger with EnVen Energy Corp. Click here for more information: https://www.monteverdelaw.com/case/talos-energy-inc .
  • We are a national class action securities litigation law firm that has recovered millions of dollars and is committed to protecting shareholders from corporate wrongdoing.
  • Also, we have recovered or secured over a dozen cash common funds for shareholders in mergers & acquisitions class action cases.

Renovacor Announces Upcoming Presentation at the 29th European Society of Gene & Cell Therapy Congress

Retrieved on: 
Monday, October 10, 2022
Biotechnology, Health, Genetics, Clinical Trials, Cardiology, Quality of life, Congress, ESGCT, Disease, Conference, IND, NYSE, Cell, Patient, Gene, CMC, Analytic, RCOR, European Society of Gene and Cell Therapy, Private Securities Litigation Reform Act, Edinburgh International Conference Centre, Company, U.S. Securities and Exchange Commission, AAV, Heart failure, Securities & Exchange Commission of Pakistan, DCM, Intellectual property, Forward-looking statement, FDA, COVID-19, Pharmaceutical industry

The congress is taking place from October 11 14, 2022, at the Edinburgh International Conference Centre in Edinburgh, Scotland.

Key Points: 
  • The congress is taking place from October 11 14, 2022, at the Edinburgh International Conference Centre in Edinburgh, Scotland.
  • REN-001 is an AAV-based gene therapy targeting BAG3-associated dilated cardiomyopathy (DCM), a severe form of heart failure.
  • The upcoming poster (P046), titled, Analytical and biophysical characterization of a rAAV9 vector for in-vivo gene therapy to treat dilated cardiomyopathy, will be presented from 5:30 7:15 p.m. British Summer Time on October 14, 2022.
  • Renovacor is a biotechnology company focused on delivering innovative precision therapies to improve the lives of patients and families battling genetically-driven cardiovascular and mechanistically-related diseases.

Renovacor Announces Upcoming Presentation at Keystone Symposia’s Heart Failure: Mechanisms and Therapies Conference

Retrieved on: 
Monday, September 26, 2022
Science, Cardiology, Biotechnology, Research, Pharmaceutical, Health, Genetics, Clinical Trials, Keystone, U.S. Securities and Exchange Commission, CO, Securities & Exchange Commission of Pakistan, COVID-19, NYSE, FDA, IND, Company, Poster, Intellectual property, DCM, Heart failure, Forward-looking statement, Patient, Quality of life, MST, Private Securities Litigation Reform Act, Heart, BAG3, Conference, RCOR, Mortality, Haploinsufficiency, Disease, Pharmaceutical industry

The conference is taking place from September 28 October 1, 2022, at the Beaver Run Resort in Breckenridge, CO.

Key Points: 
  • The conference is taking place from September 28 October 1, 2022, at the Beaver Run Resort in Breckenridge, CO.
  • The posters presenting author is Valerie Myers, Ph.D., Senior Director of Preclinical Science at Renovacor.
  • Renovacor is a biotechnology company focused on delivering innovative precision therapies to improve the lives of patients and families battling genetically-driven cardiovascular and mechanistically-related diseases.
  • The companys lead program in BAG3-associated dilated cardiomyopathy (DCM) uses gene transfer technology to address the monogenic cause of this severe form of heart failure.

SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Renovacor, Inc. (NYSE - RCOR)

Retrieved on: 
Wednesday, September 21, 2022
Suite, NYSE, Brodsky, Company, Nasdaq, Board of directors, Board, GLOBE, RCOR

The investigation concerns whether the Renovacor Board breached its fiduciary duties to shareholders by failing to conduct a fair process, and whether Rocket Pharmaceuticals is paying too little for the Company.

Key Points: 
  • The investigation concerns whether the Renovacor Board breached its fiduciary duties to shareholders by failing to conduct a fair process, and whether Rocket Pharmaceuticals is paying too little for the Company.
  • For example, the deal consideration is below the 52-week high of $10.47 for the Companys shares.
  • You may contact Jason L. Brodsky, Esquire, or Marc L. Ackerman, Esquire at Brodsky & Smith, Two Bala Plaza, Suite 805, Bala Cynwyd, PA 19004, visit https://www.brodskysmith.com/cases/renovacor-inc-nyse-rcor/ , or call toll free 855-576-4847.
  • Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits.

RCOR STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Sale of Renovacor, Inc. Is Fair to Shareholders

Retrieved on: 
Tuesday, September 20, 2022
Class Action Lawsuit, Professional Services, Legal, Advertising, RCOR, Fraud, NYSE, Sale, Security (finance)

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Renovacor, Inc. (NYSE: RCOR) to Rocket Pharmaceuticals, Inc. for approximately 0.1676 shares of Rocket for each Renovacor share is fair to Renovacor shareholders.

Key Points: 
  • Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Renovacor, Inc. (NYSE: RCOR) to Rocket Pharmaceuticals, Inc. for approximately 0.1676 shares of Rocket for each Renovacor share is fair to Renovacor shareholders.
  • Upon completion of the transaction, Renovacor shareholders are expected to own approximately 4.6% percent of Rocket.
  • On behalf of Renovacor shareholders, Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.
  • Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.